Currently, the selective Polθ inhibitor ART6043 is being evaluated in a Phase I/II clinical trial (NCT05898399), recruiting patients with HER2-negative advanced breast cancer harboring BRCA mutations (Table 3). The gene discussed is ERBB2; the disease is breast carcinoma.